Lange PH - Search Results

1

Maximal testosterone suppression in prostate cancer--free vs total testosterone.

Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO. Rove KO, et al. Among authors: lange ph. Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6. Urology. 2014. PMID: 24713136 Free PMC article. Review.

2

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Mostaghel EA, et al. J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323034 Free PMC article. Clinical Trial.

3

Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.

Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW. Sim HG, et al. Among authors: lange ph. J Urol. 2008 May;179(5):1775-9. doi: 10.1016/j.juro.2008.01.016. Epub 2008 Mar 17. J Urol. 2008. PMID: 18343432

4

Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.

Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW. Wright JL, et al. Among authors: lange ph. J Urol. 2010 Jun;183(6):2213-8. doi: 10.1016/j.juro.2010.02.017. J Urol. 2010. PMID: 20399459 Free PMC article.

5

Re: Intermittent Androgen Deprivation (IAD) in Prostate Cancer (PC): Are We Ready To Quit?

Lange PH. Lange PH. Eur Urol. 2016 Sep;70(3):542-3. doi: 10.1016/j.eururo.2016.06.028. Epub 2016 Jul 4. Eur Urol. 2016. PMID: 27387125 No abstract available.

6

Detection and isolation of prostate cancer cells from peripheral blood and bone marrow.

Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Ellis WJ, et al. Among authors: lange ph. Urology. 2003 Feb;61(2):277-81. doi: 10.1016/s0090-4295(02)02291-4. Urology. 2003. PMID: 12597930

7

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Scher HI, et al. Among authors: lange ph. J Clin Oncol. 2004 Feb 1;22(3):537-56. doi: 10.1200/JCO.2004.07.099. J Clin Oncol. 2004. PMID: 14752077

8

Newer potential biomarkers in prostate cancer.

Wright JL, Lange PH. Wright JL, et al. Among authors: lange ph. Rev Urol. 2007 Fall;9(4):207-13. Rev Urol. 2007. PMID: 18231617 Free PMC article.

9

Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.

Lange PH. Lange PH. Eur Urol. 2010 Aug;58(2):311-2. doi: 10.1016/j.eururo.2010.05.015. Eur Urol. 2010. PMID: 20845543

10

Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy.

Sim HG, Kliot M, Lange PH, Ellis WJ, Takayama TK, Yang CC. Sim HG, et al. Among authors: lange ph. Urology. 2006 Dec;68(6):1290-4. doi: 10.1016/j.urology.2006.08.1064. Epub 2006 Dec 4. Urology. 2006. PMID: 17141842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page